DK0699678T3 - Krystallinsk form af dihydro-2,3-benzodiazepinderivat - Google Patents

Krystallinsk form af dihydro-2,3-benzodiazepinderivat

Info

Publication number
DK0699678T3
DK0699678T3 DK95306052T DK95306052T DK0699678T3 DK 0699678 T3 DK0699678 T3 DK 0699678T3 DK 95306052 T DK95306052 T DK 95306052T DK 95306052 T DK95306052 T DK 95306052T DK 0699678 T3 DK0699678 T3 DK 0699678T3
Authority
DK
Denmark
Prior art keywords
dihydro
crystalline form
benzodiazepine derivative
acetyl
methyl
Prior art date
Application number
DK95306052T
Other languages
English (en)
Inventor
Benjamin Alan Anderson
Marvin Martin Hansen
Jeffrey Thomas Vicenzi
David Lee Varie
Milton Joseph Zmijewski
Edward Grant Groleau
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/412,242 external-priority patent/US6329364B1/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0699678T3 publication Critical patent/DK0699678T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK95306052T 1994-08-31 1995-08-30 Krystallinsk form af dihydro-2,3-benzodiazepinderivat DK0699678T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29864594A 1994-08-31 1994-08-31
US08/412,242 US6329364B1 (en) 1994-08-31 1995-03-28 Crystalline form of dihydro-2,3-benzodiazepine derivative

Publications (1)

Publication Number Publication Date
DK0699678T3 true DK0699678T3 (da) 2004-06-28

Family

ID=26970796

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95306052T DK0699678T3 (da) 1994-08-31 1995-08-30 Krystallinsk form af dihydro-2,3-benzodiazepinderivat

Country Status (19)

Country Link
EP (1) EP0699678B1 (da)
JP (1) JP3449835B2 (da)
CN (1) CN1073996C (da)
AT (1) ATE262531T1 (da)
AU (1) AU695424B2 (da)
BR (1) BR9503843A (da)
CA (1) CA2157248C (da)
CZ (1) CZ288679B6 (da)
DE (1) DE69532739T2 (da)
DK (1) DK0699678T3 (da)
ES (1) ES2214491T3 (da)
FI (1) FI112489B (da)
HU (1) HU223843B1 (da)
IL (1) IL115102A (da)
NO (1) NO309192B1 (da)
NZ (1) NZ272898A (da)
PL (1) PL181086B1 (da)
PT (1) PT699678E (da)
TR (1) TR199501070A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
WO1998013046A1 (en) 1996-09-27 1998-04-02 Guilford Pharmaceuticals Inc. Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
KR20010022856A (ko) * 1997-08-12 2001-03-26 사바 키스 ; 아틸라 만디 야노스 템페 ; 기울라 시미그 Ampa/카이네이트 수용체 억제제로서의 1,3-디옥솔로/4,5-h//2,3/벤조디아제핀 유도체
UA67749C2 (uk) 1997-08-12 2004-07-15 Егіш Дьйодьсердьяр Рт. Похідна 8-заміщеного-9н-1,3-діоксол/4,5-h//2,3/бензодіазепіну з властивостями амра/каїнатного антагоніста, спосіб одержання похідних, фармацевтична композиція (варіанти), спосіб її одержання та спосіб лікування

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219778B (hu) * 1990-12-21 2001-07-30 Gyógyszerkutató Intézet Közös Vállalat Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények
HU219777B (hu) * 1993-07-02 2001-07-30 Gyógyszerkutató Intézet Kft. Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására

Also Published As

Publication number Publication date
PL181086B1 (pl) 2001-05-31
PL310228A1 (en) 1996-03-04
IL115102A (en) 1998-12-27
PT699678E (pt) 2004-07-30
BR9503843A (pt) 1996-09-10
CA2157248A1 (en) 1996-03-01
HK1013820A1 (en) 1999-09-10
NZ272898A (en) 1996-12-20
JP3449835B2 (ja) 2003-09-22
JPH0881469A (ja) 1996-03-26
FI954066L (fi) 1996-03-01
HU223843B1 (hu) 2005-02-28
TR199501070A2 (tr) 1996-06-21
AU695424B2 (en) 1998-08-13
EP0699678B1 (en) 2004-03-24
FI954066A0 (fi) 1995-08-30
HUT72675A (en) 1996-05-28
AU3035795A (en) 1996-03-14
FI112489B (fi) 2003-12-15
CA2157248C (en) 2000-02-22
IL115102A0 (en) 1995-12-08
ATE262531T1 (de) 2004-04-15
CZ288679B6 (cs) 2001-08-15
DE69532739D1 (de) 2004-04-29
ES2214491T3 (es) 2004-09-16
CZ222195A3 (en) 1996-03-13
CN1073996C (zh) 2001-10-31
NO953394D0 (no) 1995-08-30
HU9502549D0 (en) 1995-10-30
CN1128264A (zh) 1996-08-07
DE69532739T2 (de) 2005-03-17
NO309192B1 (no) 2000-12-27
NO953394L (no) 1996-03-01
EP0699678A1 (en) 1996-03-06

Similar Documents

Publication Publication Date Title
FI924381A0 (fi) Derivat av pyrimidinnukleosid med tumoermotverkande effekt, framstaellning och anvaendning av dessa.
ES2054899T3 (es) Derivados de 2'-desoxi-5-fluorouridina.
MX9300222A (es) Nuevos derivados de arilcicloalquilo, su preparacion y su utilizacion.
NO992549L (no) Sukkerforbindelse, geleringsmiddel og fremgangsmåte for fremstilling derav
DE69122427D1 (de) Imidazonaphthyridinderivate
DK0382660T3 (da) Dioxaphosphorinanforbindelser og dermed stabiliserede polyolefinmaterialer
FI954066A0 (fi) Dihydro-2,3-bentsodiatsepiinijohdannaisten kiteinen muoto
DK0699676T3 (da) Fysisk form af et dihydro-2,3-benzodiazepinderivat
MY118394A (en) Crystalline form of dihydro-2, 3-benzodiazepine derivative
FI890293A0 (fi) Foerfarande foer framstaellning av tioformamidderivat.
SE8901060D0 (sv) New compounds
DE69626624D1 (de) Medikamente gegen trhombocytopenie
ES2096628T3 (es) Derivados heterociclicos.
PT90194A (pt) Processo para a preparacao de composicoes insecticidas contendo 1-dimetilcarbamoil-3-substituido-5-substituido-1h-1, 2, 4-triazois
IL78625A0 (en) Furanone derivatives and their preparation
DE60103732D1 (de) Pyrimidinderivate mit antitumor-wirkung
ATE100449T1 (de) 1,3-dioxolan-benzoesaeure und derivate davon.